Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Annexon, Inc. - common stock (NQ:ANNX)

6.080 +0.520 (+9.35%)
Streaming Delayed Price Updated: 12:53 PM EST, Jan 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Annexon, Inc. - common stock

< Previous 1 2 3 4 5 6 7 Next >
Curious about the stocks that are showing activity after the closing bell on Monday? ↗
Via Chartmill
News headline image
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
News headline image
Which stocks are moving on Wednesday? ↗
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Biosciences to Participate in Upcoming September Investor Conferences
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Narrows Loss in Fiscal Q2 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy
From Annexon Biosciences
Via GlobeNewswire
News headline image
Thursday's session: gap up and gap down stocks ↗
Let's have a look at what is happening on the US markets on Thursday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
News headline image
Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Stanley Black & Decker To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder ↗
Annexon's tanruprubart showed significant and sustained functional gains in Guillain-Barré patients, meeting key Phase 3 trial endpoints. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.